Vera Therapeutics, Inc. Class A Share Price
NASDAQ: VERA | Mid CapVera Therapeutics, Inc. Class A Stock Performance
Open $32.80 | Prev. Close $32.08 | Circuit Range N/A |
Day Range $32.14 - $33.03 | Year Range $19.17 - $56.01 | Volume 65,295 |
Average Traded $32.61 |
Vera Therapeutics, Inc. Class A Share Price Today
As of 9 August 2026, Vera Therapeutics, Inc. Class A's share price is $32.86. The stock opened at $32.80, compared to its previous close of $32.08. During today's trading session, Vera Therapeutics, Inc. Class A's share price traded between $32.14 and $33.03, with an average price of $32.59. Over the past 52 weeks, the stock has recorded a high of $56.01 and a low of $19.17. In terms of performance, Vera Therapeutics, Inc. Class A's share price has declined by 19.48% over the last six months and is up 51.88% on a year-on-year basis.
Vera Therapeutics, Inc. Class A Share Price Chart
Vera Therapeutics, Inc. Class A Stock Fundamentals & Key Indicators
Market Cap $2.11B | PE Ratio (TTM) -7.05 | Dividend Yield N/A |
EPS (TTM) $-4.66 | Revenue (TTM) N/A | Return On Equity (TTM) -49.56% |
Profit Margin N/A | Debt to Equity 0.09 | Quarterly Earnings Growth YoY -72.18% |
Vera Therapeutics, Inc. Class A Quarterly Profit & Loss
All figures in USD
Vera Therapeutics, Inc. Class A Annual Profit & Loss
All figures in USD
About Vera Therapeutics, Inc. Class A
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Vera Therapeutics, Inc. Class A Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $31.41 | $32.90 | +2.51% |
Jul 2026 | $42.75 | $32.09 | -25.25% |
Jun 2026 | $34.70 | $42.93 | +20.78% |
May 2026 | $34.79 | $35.55 | -0.18% |
Apr 2026 | $41.01 | $35.61 | -11.38% |
Mar 2026 | $40.13 | $40.19 | -1.53% |
Feb 2026 | $43.29 | $40.81 | -5.65% |
Jan 2026 | $50.74 | $43.26 | -14.53% |
Dec 2025 | $33.09 | $50.61 | +49.53% |
Nov 2025 | $28.34 | $33.84 | +19.07% |
Oct 2025 | $29.24 | $28.43 | -2.25% |
Sep 2025 | $21.82 | $29.08 | +34.41% |
VERA Share Price FAQs
What is Vera Therapeutics, Inc. Class A share price today?
What is the 52 week high and 52 week low of Vera Therapeutics, Inc. Class A stock?
What is VERA's market capitalisation today?
What is VERA's net income for the last quarter?
What is the 5 year returns of VERA?
What is the high & low stock price of VERA today?
Can I buy VERA shares in India?